clinical trial · NCT06723405
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
Atopic Dermatitis (AD)EczemaEczema Atopic DermatitisEVO301Placebo
brief summary
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
started
Feb 13, 2025
primary completion
Nov 17, 2025
completion
Nov 17, 2025
last updated
Dec 4, 2025
detailed description
This is a Phase 2a efficacy and safety study of intravenous EVO301 in adults with moderate to severe atopic dermatitis.
official title
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study of EVO301 in Adults With Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol